HC Wainwright reaffirmed their buy rating on shares of Cytosorbents (NASDAQ:CTSO – Get Rating) in a research report report published on Friday morning, Benzinga reports. They currently have a $5.50 target price on the medical research company’s stock.
Separately, StockNews.com raised Cytosorbents from a sell rating to a hold rating in a research note on Friday.
Cytosorbents Stock Performance
Shares of NASDAQ CTSO opened at $3.28 on Friday. The company has a quick ratio of 3.12, a current ratio of 3.47 and a debt-to-equity ratio of 0.14. The business’s 50 day moving average is $2.87 and its two-hundred day moving average is $2.02. The company has a market cap of $142.99 million, a P/E ratio of -4.37 and a beta of 0.77. Cytosorbents has a 12 month low of $1.03 and a 12 month high of $4.59.
Hedge Funds Weigh In On Cytosorbents
Cytosorbents Company Profile
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Princeton, NJ.
- Get a free copy of the StockNews.com research report on Cytosorbents (CTSO)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.